Showing 42,001 - 42,020 results of 42,065 for search '"China"', query time: 0.27s Refine Results
  1. 42001
  2. 42002
  3. 42003
  4. 42004
  5. 42005
  6. 42006

    Dual targeting PD-L1 and 4-1BB to overcome dendritic cell-mediated lenalidomide resistance in follicular lymphoma by Zhong Zheng, Jian-Biao Wang, Rui Sun, Nan Wang, Xiang-Qin Weng, Tian-Yuan Xu, Di Fu, Yan Feng, Peng-Peng Xu, Shu Cheng, Li Wang, Yan Zhao, Bin Qu, Chuan-Xin Huang, Wei-Li Zhao

    Published 2025-01-01
    “…We conducted the first trial of immunotherapy rituximab plus lenalidomide in newly diagnosed FL in China (NCT03715309). One-hundred and fifteen patients were enrolled and treated with rituximab 375 mg/m2 intravenously on day 0 and lenalidomide 25 mg orally on day 1–10 for 6 cycles of induction treatment, as well as lenalidomide for 6 cycles and rituximab for 8 cycles of maintenance treatment. …”
    Get full text
    Article
  7. 42007
  8. 42008
  9. 42009
  10. 42010
  11. 42011
  12. 42012
  13. 42013
  14. 42014
  15. 42015

    Exploration of rituximab treatment strategies for membranous nephropathy adapted to the Chinese healthcare environment by Xiaolong Wang, Xueying Cao, Jie Wu, Shuang Liang, Jian Yang, Hong Wang

    Published 2025-01-01
    “…Abstract Purpose This study aimed to explore the specific efficacy of rituximab (RTX) in the treatment of membranous nephropathy (MN) and compare and analyze the differences in effectiveness among various treatment regimens, with the objective of identifying the optimal treatment protocol suitable for the medical environment in China. Patients and methods This retrospective study focused on patients with MN who were treated with RTX and hospitalized at the First Medical Center of PLA General Hospital between January 1, 2019, and December 30, 2022. …”
    Get full text
    Article
  16. 42016
  17. 42017
  18. 42018

    Multi-cancer early detection tests for general population screening: a systematic literature review by Ros Wade, Sarah Nevitt, Yiwen Liu, Melissa Harden, Claire Khouja, Gary Raine, Rachel Churchill, Sofia Dias

    Published 2025-01-01
    “…Studies assessed the following MCED tests: Galleri® (GRAIL, Menlo Park, CA, USA), CancerSEEK (Exact Sciences, Madison, WI, USA), SPOT-MAS™ (Gene Solutions, Ho Chi Minh City, Vietnam), Trucheck™ (Datar Cancer Genetics, Bayreuth, Germany), CDA (Cancer Differentiation Analysis; AnPac Bio, Shanghai, China) and AICS® (AminoIndex Cancer Screening; Ajinomoto, Tokyo, Japan). …”
    Get full text
    Article
  19. 42019
  20. 42020